CytoDyn (CYDY) EBIT Margin (2021 - 2022)

CytoDyn (CYDY) posted EBIT Margin of 232494.12% for Q2 2022, down 1965.84% on a QoQ basis from 11254.22% in Q4 2021.

CytoDyn (CYDY) EBIT Margin (2021 - 2022) Analysis & Trends

CytoDyn's EBIT Margin history runs 2 years deep, the most recent figure standing at 232494.12% for Q2 2022.

Quarterly EBIT Margin changed N/A year-over-year to 232494.12% in Q2 2022, while the trailing twelve-month figure through May 2022 was 48468.0% (changed N/A YoY) and the FY2022 annual result came in at 48468.0%, changed N/A from the prior year.
EBIT Margin was 232494.12% for Q2 2022 at CytoDyn, down from 11254.22% in the prior quarter.
Across five years, EBIT Margin topped out at 11254.22% in Q4 2021 and bottomed at 232494.12% in Q2 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	CytoDyn	267.79 Mn	267.79 Mn	-	-

Historic Data

Download Data

Date	Value
May 31, 2022	-232,494.12%
Nov 30, 2021	-11,254.22%
Aug 31, 2021	-52,773.17%